
    
      To assess long term safety and tolerability of subjects who discontinue for any reason from
      UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these
      patients. The trial was terminated prematurely on January 29, 2013, due to the decision of
      the sponsor to discontinue development of lersivirine. The decision to terminate the trial
      was not based on any safety or efficacy concerns.
    
  